Although there is no known treatment for COVID19, researchers have created a new antibody that neutralises SARS-CoV-2 (the virus that causes COVID-19) in cells, providing the possibility of preventing and treating coronaviruses. The study, published in Nature Communications, suggests that an antibody called 47D11, produced in a laboratory environment, effectively suppresses the spike proteins found in SARS-CoV-2 and SARS-CoV.
“Our data show that 47D11 is “moderated” to SARS-CoV and SARS-CoV-2 through an unknown mechanism that differs from receptor binding interference,” the researchers wrote in the study. “
Sars-CoV, also known as Severe Acute Respiratory Syndrome (SARS), first appeared in China in 2002 and erupted in SARS between 2002 and 2004.
According to the U.S. Centers for Disease Control and Prevention (CDC), the virus is linked to horseshoe bats and has killed many people.
The Mayo Clinic says the 47D11 antibody is a monoclonal antibody that has previously been used in anti-cancer drugs.
The Mayo Clinic added that monoclonal antibodies are defined as “laboratory-produced molecules used to replace antibodies.”
The researchers note that the development of this potential drug is still in its early stages, but promising.
The researchers say the 47D11 ties a conservative epidermis to the spike RBD, crossing “middle” to SARS-CoV and SARS-CoV-2. This is also the first report on human monoclonal antibodies “neutralizing” SARS-CoV-2.
“This antibody will help develop antigen testing and serological testing for SARS-CoV-2,” the researchers added. Neutralizing antibodies can alter the infection process of an infected host, support virus removal, or protect uninfected hosts exposed to the virus. “
“As a result, this antibody, whether used alone or in combination, has the potential to prevent and treat COVID-19 and possibly prevent or treat other new human diseases caused by sarbeco virus subgenous viruses.” “